Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof

A method of treating a mast cell-mediated inflammatory joint disease, comprising:

• injecting a plurality of sustained release particles into a joint of a patient in need thereof, wherein:
• said patient joint is affected by said inflammatory joint disease, and
• the sustained release particles comprise a therapeutically effective amount of a tyrosine kinase inhibitor.

A method of treating a mast cell-mediated inflammatory disease, comprising:

• local administration of a plurality of sustained release particles to a patient in need thereof, wherein:
• said patient is affected by said mast cell-mediated inflammatory disease, and the sustained release particles comprise a therapeutically effective amount of a tyrosine kinase inhibitor.

A pharmaceutical composition comprising a plurality of sustained release particles comprising a biodegradable polymer and a tyrosine kinase inhibitor, wherein said sustained release particles have a biomodal particle size distribution which provides 10% TKI release per week and provide therapeutically effective levels of TKI for 2 months.